Home > In process > Time‑resolved multi-omic analysis of paclitaxel exposure in human iPSC‑derived sensory neurons unveils mechanisms of chemotherapy‑induced peripheral neuropathy. > print

001     285355
005     20260225105232.0
024 7 _ |a 10.1038/s41419-026-08445-2
|2 doi
024 7 _ |a pmid:41667428
|2 pmid
024 7 _ |a pmc:PMC12921266
|2 pmc
037 _ _ |a DZNE-2026-00221
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Schinke, Christian
|0 0000-0003-0199-9672
|b 0
245 _ _ |a Time‑resolved multi-omic analysis of paclitaxel exposure in human iPSC‑derived sensory neurons unveils mechanisms of chemotherapy‑induced peripheral neuropathy.
260 _ _ |a London [u.a.]
|c 2026
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772013072_9599
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The microtubule-stabilizing drug paclitaxel remains the standard of care for various solid malignancies but frequently leads to chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a leading cause for premature treatment termination and a significantly reduced quality of life in long-term cancer survivors. The molecular mechanisms of neuro-axonal degeneration, neuroinflammation, and pain in patients treated with paclitaxel remain incompletely understood, and there are currently no predictive biomarkers or preventive treatments. We used human iPSC-derived sensory neurons exposed to paclitaxel to comprehensively model the pathophysiology of CIPN. Neurotoxicity was assessed over time using viability assays and sequential RNA sequencing, as well as deep proteome and lipidomic analyses. We observed a time and dose-dependent decline of cell viability at clinically relevant paclitaxel doses. Sequential RNA sequencing defined JUN as an early immediate gene, followed by the overexpression of genes of the neuronal stress response (e.g., ARID5A, WEE1, DUSP16, GADD45A), neuronal injury and apoptotic pathways (e.g., ATF3, HRK, BBC3 [PUMA], BCL2L11 [BIM], CASP3), neuroinflammation and nociception (CALCB, MMP10, IL31RA, CYSLTR2, C3AR1, TNFRSF12A) and neuronal transduction (e.g., CAMK2A, STOML3, PIRT), while key enzymes of lipid biosynthesis were markedly downregulated (e.g., LSS, HMGCS1, HMGCR, DHCR24). Deep proteome analyses following 48 h of exposure to 100 nM paclitaxel revealed a strong correlation of differentially expressed RNA with proteins, and a marked degradation of essential axonal transport proteins such as kinesins, stathmins, and scaffold proteins. Consistent with the downregulation of rate-limiting enzymes of lipid biosynthesis, lipidome analysis confirmed deregulation of neuronal lipid homeostasis. In summary, paclitaxel induces transcriptomic and proteomic signatures of the neuronal stress response, neuroinflammation, nociception, and disturbed metabolism. These may explain, in part, the clinical phenotype of sensory loss, hypersensitivity, and neuropathic pain frequently observed in patients suffering from CIPN, but constitute pharmacologically addressable targets.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Paclitaxel
|0 P88XT4IS4D
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Paclitaxel: adverse effects
|2 MeSH
650 _ 2 |a Paclitaxel: pharmacology
|2 MeSH
650 _ 2 |a Peripheral Nervous System Diseases: chemically induced
|2 MeSH
650 _ 2 |a Peripheral Nervous System Diseases: pathology
|2 MeSH
650 _ 2 |a Peripheral Nervous System Diseases: metabolism
|2 MeSH
650 _ 2 |a Peripheral Nervous System Diseases: genetics
|2 MeSH
650 _ 2 |a Sensory Receptor Cells: drug effects
|2 MeSH
650 _ 2 |a Sensory Receptor Cells: metabolism
|2 MeSH
650 _ 2 |a Sensory Receptor Cells: pathology
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: metabolism
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: drug effects
|2 MeSH
650 _ 2 |a Cell Survival: drug effects
|2 MeSH
650 _ 2 |a Multiomics
|2 MeSH
700 1 _ |a Maierhof, Smilla K
|b 1
700 1 _ |a Hew, Lois
|0 0000-0002-0183-8177
|b 2
700 1 _ |a Fernandez Vallone, Valeria
|b 3
700 1 _ |a Frahm, Silke
|0 0000-0001-5645-2557
|b 4
700 1 _ |a Telugu, Narasimha Swamy
|b 5
700 1 _ |a Diecke, Sebastian
|b 6
700 1 _ |a Ivanov, Andranik
|b 7
700 1 _ |a Kovács, Richard
|b 8
700 1 _ |a Beule, Dieter
|b 9
700 1 _ |a Kirchner, Marieluise
|0 0000-0002-7049-534X
|b 10
700 1 _ |a Mertins, Philipp
|0 0000-0002-2245-528X
|b 11
700 1 _ |a Brüning, Ulrike
|b 12
700 1 _ |a Kirwan, Jennifer A
|0 0000-0002-5423-1651
|b 13
700 1 _ |a Stachelscheid, Harald
|0 0000-0002-9283-4605
|b 14
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 15
700 1 _ |a Huehnchen, Petra
|0 0000-0002-6825-7270
|b 16
700 1 _ |a Boehmerle, Wolfgang
|0 0000-0001-7195-3894
|b 17
773 _ _ |a 10.1038/s41419-026-08445-2
|g Vol. 17, no. 1, p. 211
|0 PERI:(DE-600)2541626-1
|n 1
|p 211
|t Cell death & disease
|v 17
|y 2026
|x 2041-4889
856 4 _ |u https://pub.dzne.de/record/285355/files/DZNE-2026-00221.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285355/files/DZNE-2026-00221.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL DEATH DIS : 2022
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T13:57:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T13:57:57Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-08-21T13:57:57Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2025-08-21T13:57:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL DEATH DIS : 2022
|d 2025-11-12
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-12
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21